Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1982 Vaccine for Lyme Disease Prevention in Healthy Adults
NCT07561294Phase 2Active, not recruiting
- Sponsor
- Moderna Inc
- Start
- Apr 2026
- Primary completion
- Nov 2028
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mRNA-1982 in Lyme disease (2 arms), sponsored by Moderna Inc. Primary endpoints: Number of Participants with Solicited Local and Systemic Adverse Reactions, Number of Participants with Unsolicited Adverse Events and 1 more. Started Apr 2026; status: active, not recruiting.
02
Drugs
mRNA-1982
03
Conditions
Lyme disease
Beyond the preview
Go deeper on NCT07561294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07561294.